Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02452749 · ClinicalTrials.gov registry record · NA
Prospective Safety and Tolerability Assessment of a Cardiovascular Health Dietary Supplement
A NA study, sponsored by National University of Natural Medicine.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT02452749: Completed NA study, sponsored by National University of Natural Medicine.
NCT02452749 is a NA study that has completed, run by National University of Natural Medicine. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02452749, a NA study, has completed, sponsored by National University of Natural Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
This single-arm, open-label study will assess the safety and tolerability of one daily tablet of a commercially available cardiovascular health dietary supplement by questionnaire and blood markers in adults with borderline to mild hypertension over a 6 month period. Although the cardiovascular health dietary supplement being investigated has been on the market for over 20 years, prospective safety data and blood markers of end organ function have not previously been reported.
Primary Outcome
Standardized adverse event monitoring form, Patient Health Questionnaire (PHQ-9), electrolytes (sodium, potassium, calcium, magnesium), b-type natriuretic peptide, aspartate aminotransferase, alanine aminotransferase, and estimated glomerular filtration rate
Interventions
- DIETARY_SUPPLEMENT Cardiovascular health dietary supplement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2015-05-01 |
| Est. Completion | 2017-07-28 |
| Phase | NA |
What the finished NCT02452749 record still lists
NCT02452749 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Cardiovascular health dietary supplement is the first listed.
NCT02452749 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02452749 about?
NCT02452749 is a clinical study titled "Prospective Safety and Tolerability Assessment of a Cardiovascular Health Dietary Supplement". This single-arm, open-label study will assess the safety and tolerability of one daily tablet of a commercially available cardiovascular health dietary supplement by questionnaire and blood markers in adults with borderline to mild hypertension over a 6 month period. Although the cardiovascular heal...
What is the current status of trial NCT02452749?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2015-05-01. Estimated completion is 2017-07-28.
What interventions are being tested in trial NCT02452749?
The interventions under investigation include: Cardiovascular health dietary supplement (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02452749?
This trial is sponsored by National University of Natural Medicine, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02452749's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI